research use only

Omaveloxolone (RTA-408) NRF2 activator

Cat.No.S7672

Omaveloxolone (RTA-408) is a synthetic triterpenoid that activates the cytoprotective transcription factor Nrf2 and inhibits NF-κB signaling. Phase 2.
Jump to

Quality Control

Batch: Purity: 99.91%
99.91

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (180.27 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 3 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 554.71 Formula

C33H44F2N2O3

Storage (From the date of receipt)
CAS No. 1474034-05-3 Download SDF Storage of Stock Solutions

Synonyms N/A SMILES CC1(CCC2(CCC3(C(C2C1)C(=O)C=C4C3(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)C)NC(=O)C(C)(F)F)C

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
NF-κB
Nrf2
In vitro
RTA 408 potently increases expression of Nrf2 target genes and reverses IFNγ-mediated suppression of Gclc expression in RAW 264.7 cells. In a panel of eight human tumor cell lines, RTA 408 inhibits growth with an average GI50 value of 260 nM and induces apoptosis. RTA 408 also inhibits NF-κB and activates JNK in tumor cells.
In vivo
In mice with radiation-induced dermatitis, 1.0% RTA 408 markedly reduces epidermal and collagen thickening, prevents dermal necrosis and completely alleviates skin ulcers. In rat skin, RTA 408 activates Nrf2 and induces cytoprotective genes. RTA 408 also mitigates hematopoietic acute radiation syndrome in mice.
References
  • [4] https://pubmed.ncbi.nlm.nih.gov/25738896/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-09-03)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06054893 ACTIVE_NOT_RECRUITING
Friedreich Ataxia
Biogen
2024-07-01 PHASE1
NCT06953583 RECRUITING
Friedreich Ataxia
Biogen
2025-06-09 PHASE3
NCT07297199 COMPLETED
Healthy Volunteer
Biogen
2025-12-12 PHASE1
NCT07149415 COMPLETED
Healthy Volunteer
Biogen
2025-09-02 PHASE1
NCT07019064 COMPLETED
Healthy Volunteer
Biogen
2025-06-11 PHASE1
NCT06612879 COMPLETED
Healthy Volunteer
Biogen
2024-10-18 PHASE1

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map